Document Detail

Is It Time to Translate Ischemic Preconditioning's Mechanism of Cardioprotection into Clinical Practice?
MedLine Citation:
PMID:  21821528     Owner:  NLM     Status:  In-Data-Review    
After three decades of intense research on cardioprotection, we still do not have an approved intervention for limiting infarct size in the patient with acute myocardial infarction (AMI) aside from reperfusion therapy. Yet approximately 25% of patients with AMI that are reperfused are still at risk for heart failure because of excessive muscle necrosis. This article will try to make the case that ischemic preconditioning (IPC), still the most potent anti-infarct intervention ever described, is ready for serious clinical testing now. Over the past 25 years, IPC's mechanism has been largely elucidated and targets a reperfusion injury. Ischemic preconditioning was never considered an intervention for AMI because of its need for pretreatment. However, knowledge of IPC's mechanism has revealed a large number of drugs and interventions that will activate IPC's signaling pathway at the time of reperfusion. Several small clinical trials suggest that they can be quite effective, but so far industry seems to have little interest in developing them. So, while basic scientists are in a continuous cycle of discovery and publication for new and novel cardioprotectants, there has been little effort devoted to translating these interventions into clinical practice. We believe that there are suitable IPC-based interventions that are ready for clinical testing today and the time has come for large-scale clinical trials.
Michael V Cohen; James M Downey
Related Documents :
21140118 - Clinics in diagnostic imaging (132). vein of galen malformation.
22488008 - Can early cardiac troponin i measurement help to predict recent coronary occlusion in o...
22498998 - Relationship of fragmented qrs complexes with inadequate coronary collaterals in patien...
22459388 - Effects of vitamin d supplementation on markers of vascular function after myocardial i...
19455568 - Electrocardiographic abnormalities in young athletes with mitral valve prolapse.
1629258 - Non-q-wave myocardial infarction: a prognostic paradox.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology and therapeutics     Volume:  16     ISSN:  1940-4034     ISO Abbreviation:  J. Cardiovasc. Pharmacol. Ther.     Publication Date:  2011 Sep 
Date Detail:
Created Date:  2011-08-08     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602617     Medline TA:  J Cardiovasc Pharmacol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  273-80     Citation Subset:  IM    
1Department of Physiology, University of South Alabama, College of Medicine, Mobile, AL, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The role of comorbidities in cardioprotection.
Next Document:  Cardioprotection by ivabradine through heart rate reduction and beyond.